Articles

Biogen Idec expands oncology pipeline, acquires Conforma Therapeutics

In a move that will expand its oncology pipeline, Biogen Idec announced the signing of a definitive merger agreement for the acquisition of Conforma Therapeutics Corp.
Written byJeffrey Bouley
| 2 min read

CAMBRIDGE, Mass.—In a move that will expand its oncology pipeline, and perhaps its neurological and immunological discovery efforts, Biogen Idec announced in early May the signing of a definitive merger agreement for the acquisition of Conforma Therapeutics Corp., a privately held biopharmaceutical company focused on the design and development of novel drugs for the treatment of cancer.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.